SomnoMed positions its SomnoDent devices as an alternative to the CPAP machines many patients struggle to tolerate. The Business has been growing Revenue and margins, but softer conditions in Europe and currency headwinds have complicated the FY26 picture, leaving investors to weigh a solid Earnings trajectory against a revenue miss.

What Just Happened?

On 27 July 2026 SomnoMed released a preliminary, unaudited FY26 update. Revenue was expected to come in at A$114 million to A$115 million, falling short of its prior guidance range of A$119 million to A$126 million. The company attributed the shortfall to weaker European market dynamics and adverse foreign exchange movements, noting that reimbursement policy changes and altered referral pathways had slowed patient access to oral appliance therapy.

Despite the softer revenue, SomnoMed said EBITDA was expected to land toward the middle of its A$10 million to A$12 million guided range, reflecting cost discipline. That would still represent double-digit EBITDA growth. The picture built on a strong first half, reported on 27 February 2026, in which the company posted record revenue of A$60.7 million, up 13 per cent from A$53.7 million, and EBITDA of A$7.8 million, up 35 per cent, with the EBITDA Margin expanding about 200 basis points to 13 per cent.

The update also brought a Leadership change. Co-chief executive Amrita Blickstead stepped down, leaving Karen Borg as sole chief executive. At the same time, SomnoMed began a controlled global release of Virtus, a purpose-built oral appliance for patients who have both obstructive sleep apnoea and sleep bruxism, a group the company estimates makes up around half of OSA patients. Full audited FY26 results and formal FY27 guidance are scheduled for release around 28 August 2026.

Why It Matters

The revenue miss matters because it shows how sensitive SomnoMed is to conditions in individual markets, particularly Europe, and to currency swings. Reimbursement and referral pathways determine how easily patients can access oral appliance therapy, so policy changes can slow growth even when the underlying product Demand is intact.

The more encouraging signal is that EBITDA is expected to hold up near the middle of guidance despite the lighter revenue. That points to a business that is managing its cost base and improving profitability as it scales, which is significant for a company that has historically operated close to break-even at the net line. The leadership consolidation under a single chief executive and the launch of Virtus add strategic dimensions, suggesting management is trying to sharpen focus and open a new patient segment at the same time.

The Bigger Picture

SomnoMed is an Australian medical device company built around SomnoDent continuous open airway therapy, or COAT. Its devices are custom oral appliances that reposition the lower jaw during sleep to keep the airway open, treating obstructive sleep apnoea without the mask and pump of a CPAP machine. The appliances are aimed particularly at patients who cannot tolerate CPAP, a sizeable group given well-documented compliance challenges with that therapy.

The company sells internationally, with meaningful exposure to North America and Europe, which is why currency movements and regional reimbursement policies feed directly into its results. Its growth strategy leans on expanding the addressable market, improving clinician and payer confidence, and rolling out next-generation products.

Two products frame that strategy. Virtus targets the large and underserved segment of patients who have both sleep apnoea and bruxism. Separately, the company has been developing Rest Assure, a next-generation device with built-in compliance monitoring that has received US regulatory clearance, described as the first oral appliance of its kind with that feature. Compliance data can help address physician confidence and insurance reimbursement, two of the biggest hurdles to wider adoption of oral appliances in the United States, with a soft commercial launch anticipated in FY27.

What Could Drive the Shares Next?

The most immediate catalyst is the full audited FY26 result and formal FY27 guidance, due around 28 August 2026. Investors will look to confirm the preliminary revenue and EBITDA figures and to hear management's outlook, having flagged a target of high single-digit revenue growth in FY27 while maintaining EBITDA margins consistent with FY26.

The commercial reception of Virtus, now in controlled global release, is another factor, as is progress toward the anticipated FY27 soft launch of the Rest Assure compliance-monitoring device. Any stabilisation in European reimbursement conditions, a more favourable currency backdrop, or evidence that new CEO Karen Borg is executing on cost discipline and growth could also influence sentiment.

Risks Investors Should Watch

The FY26 update highlighted several risks in plain terms. European market weakness, reimbursement policy changes and adverse foreign exchange all pressured revenue, and any of these could persist. Because SomnoMed earns much of its revenue offshore, currency remains a continuing swing Factor on both revenue and reported earnings.

Bottom Line

SomnoMed offers exposure to a growing market for alternatives to CPAP, backed by a record first half, expanding margins and a product pipeline aimed at underserved patient groups. The late-July update, however, was a reminder that revenue can disappoint even when profitability holds, with European weakness and currency dragging FY26 revenue to A$114 million to A$115 million, below the prior guidance range.

For investors, the balance sits between a resilient EBITDA trajectory and genuine top-line challenges in key markets. The full-year result and FY27 guidance around 28 August 2026, the rollout of Virtus and progress on the Rest Assure compliance device will shape the next chapter. SomnoMed remains a story of a differentiated sleep-therapy business working to convert steady operational progress into durable, profitable growth.